NCT00498836已完成2 期
A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 11
- 主要终点
- • Objective tumour response
研究概览
简要总结
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.
详细描述
This is a multicentre clinical study conducted in the USA and in Europe. It is an open label study designed to investigate objective tumor response, the time to progression (TTP) and the duration of tumor response in patients with metastatic malignant melanoma when treated with CP-4055 in combination with sorafenib (Nexavar®). The safety and tolerability of the treatment will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histological or cytological confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have or have not undergone prior chemotherapy for the treatment of melanoma
- •Measurable disease according to Response Criteria In Solid Tumors (RECIST)
- •Performance Status 0 - 1 according to ECOG (Eastern Cooperative Oncology Group) Performance Status
- •Age 18 years or more
- •Life expectancy > 3 months
- •Signed informed consent
- •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study
- •Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose
- •Adequate haematological and biological functions
排除标准
- •Known brain metastases
- •Diagnosis of ocular malignant melanoma
- •Radiotherapy to more than 30 % of bone marrow
- •Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study
- •Requirement of concomitant treatment with a non-permitted medication:
- •Alternative drugs
- •High doses of vitamins
- •History of allergic reactions to ara-C or egg
- •History of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib
- •Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection)
- •Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance
- •Pregnancy, breastfeeding or absence of adequate contraception for both male and female fertile patients
- •Known positive status for HIV and/or hepatitis B or C
- •Drug and/or alcohol abuse
- •Any reason why, in the investigator's opinion, the patient should not participate
- •Prior treatment with CP-4055 and/or sorafenib
- •Significant history of cardiac disease, including any of the following:
- •Uncontrolled hypertension
- •Unstable angina pectoris
- •Congestive heart failure
- •Myocardial infarction within the past 6 months
- •Unstable ventricular arrhythmia
- •Other cardiac arrhythmia
- •Condition that impairs ability to swallow pills
- •Tendency of bleeding
结局指标
主要结局
• Objective tumour response
时间窗: October 2008
次要结局
- • Time to progression(October 2008)
- • Duration of tumour response(October 2008)
- • Safety and tolerability of treatment(October 2008)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Clinical Study of Previously Untreated Patients With Malignant MelanomaMalignant MelanomaNeoplasm MetastasisNCT00232726Clavis Pharma42
已完成
2 期
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaMetastatic MelanomaSkin CancerNCT00665470National Cancer Institute (NCI)10
已完成
1 期
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic MalignanciesHematologic MalignanciesAMLNCT00405743Clavis Pharma153
已完成
2 期
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal CancerAdvanced Colorectal CancerColorectal CancerNCT00498407Clavis Pharma16
已完成
1 期
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic MelanomaMetastatic MelanomaNCT00609011Myrexis Inc.22